Amyotrophic Lateral Sclerosis
"Amyotrophic Lateral Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Descriptor ID |
D000690
|
| MeSH Number(s) |
C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050
|
| Concept/Terms |
Amyotrophic Lateral Sclerosis- Amyotrophic Lateral Sclerosis
- Sclerosis, Amyotrophic Lateral
- Charcot Disease
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Lou Gehrig Disease
- Lou Gehrig's Disease
- Lou-Gehrigs Disease
- Disease, Lou-Gehrigs
- ALS (Amyotrophic Lateral Sclerosis)
- Gehrig's Disease
- Gehrig Disease
- Gehrigs Disease
Amyotrophic Lateral Sclerosis, Guam Form- Amyotrophic Lateral Sclerosis, Guam Form
- Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam
- Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam
- Guam Form of Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1
- Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1
- Guam Disease
- Disease, Guam
|
Below are MeSH descriptors whose meaning is more general than "Amyotrophic Lateral Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Amyotrophic Lateral Sclerosis".
This graph shows the total number of publications written about "Amyotrophic Lateral Sclerosis" by people in this website by year, and whether "Amyotrophic Lateral Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 6 | 1 | 7 |
| 2009 | 3 | 0 | 3 |
| 2010 | 10 | 0 | 10 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 0 | 2 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 1 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 11 | 1 | 12 |
| 2017 | 5 | 0 | 5 |
| 2018 | 7 | 1 | 8 |
| 2019 | 7 | 3 | 10 |
| 2020 | 3 | 1 | 4 |
| 2021 | 6 | 1 | 7 |
| 2022 | 5 | 0 | 5 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amyotrophic Lateral Sclerosis" by people in Profiles.
-
MATR3 pathogenic variants differentially impair its cryptic splicing repression function. FEBS Lett. 2024 Feb; 598(4):415-436.
-
Respiratory Function Changes as Early Signs of Amyotrophic Lateral Sclerosis. Respiration. 2023; 102(11):919-923.
-
Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial. J Neurotrauma. 2023 09; 40(17-18):1889-1906.
-
Aggregation of Disordered Proteins Associated with Neurodegeneration. Int J Mol Sci. 2023 Feb 08; 24(4).
-
Identification of dysregulated canonical pathways associated with pathogenesis and progression of Amyotrophic Lateral Sclerosis-An integrated bioinformatics approach. Adv Protein Chem Struct Biol. 2023; 134:21-52.
-
LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 2023 02; 145(2):159-173.
-
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. Cell Rep. 2022 10 25; 41(4):111508.
-
Nucleoporins are degraded via upregulation of ESCRT-III/Vps4 complex in Drosophila models of C9-ALS/FTD. Cell Rep. 2022 09 20; 40(12):111379.
-
Loss of Activity-Induced Mitochondrial ATP Production Underlies the Synaptic Defects in a Drosophila Model of ALS. J Neurosci. 2022 10 19; 42(42):8019-8037.
-
Caspar, an adapter for VAPB and TER94, modulates the progression of ALS8 by regulating IMD/NF?B-mediated glial inflammation in a Drosophila model of human disease. Hum Mol Genet. 2022 08 25; 31(17):2857-2875.